Raiffeisen Bank International AG Makes New $176,000 Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Raiffeisen Bank International AG bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, HoldingsChannel.com reports. The fund bought 1,465 shares of the biotechnology company’s stock, valued at approximately $176,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after purchasing an additional 117,904 shares during the period. Capital International Investors boosted its stake in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after purchasing an additional 285,100 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 0.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock valued at $237,901,000 after purchasing an additional 10,343 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after purchasing an additional 9,999 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $36.43 on Monday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $3.58 billion, a P/E ratio of 29.14 and a beta of 0.85. The business has a fifty day simple moving average of $60.11 and a two-hundred day simple moving average of $97.18. Sarepta Therapeutics, Inc. has a 12 month low of $34.10 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business’s quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.73 EPS. On average, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. UBS Group dropped their price objective on Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Needham & Company LLC dropped their price objective on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Evercore ISI lowered Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target for the company. in a research note on Thursday, May 8th. Guggenheim cut their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank of Canada cut their price target on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.36.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.